negative seeking alpha article, page-15

I read the article. The problem is obviously the slow enrollment, which gives the illusion of an indefinite delay for FDA approval. That's simply nonsense.

Today's selloff was overkill. Nearly 2 million shares changed hands. Someone managed to purchase a whole lot of SSH at fire sale prices (wish it was me), while the shorts made out like bandits.

Look, slow enrollment is an eminently FIXABLE problem. SSH management is very much aware of the issue. They are hiring people to get enrollment up to speed. It's a clear problem that can be solved.

I would be far more concerned of there were medical or design problems with the device. The SA article seems to argue that C-Pulse could be too effective, and patients who are weaned off would be ignored by the FDA. This is ridiculous!

Would a tumor-shrinking drug in FDA trials be considered a failure if, rather than merely reducing the size of tumors, it eliminated them entirely for some patients? Would the FDA ignore "cured" patients? I sure hope not!

Better-than-expected results does not equal failure.

And for the record, I did not sell a single share of SSH today.